Telix Pharmaceuticals Limited: Illuccix Approved in the United Kingdom
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare ...
Aytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
Net income of $0.8 millionAdjusted EBITDA1 of $1.3 millionPediatric Portfolio net revenue up 86% sequentiallyFirst quarterly sequential prescription increase for both ADHD and Pediatric portfolios sin ...